Home › Trial NCT05325632
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Trial IDNCT05325632
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorH. Lee Moffitt Cancer Center and Research Institute
- Enrollment53
- Start date2021-10-28
- ConditionsHER2-positive Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.